DOCSLIB.ORG

FLT3/D835Y Mutation Knock-In Mice Display Less Aggressive

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FLT3/D835Y Mutation Knock-In Mice Display Less Aggressive FLT3/D835Y mutation knock-in mice display less SEE COMMENTARY aggressive disease compared with FLT3/internal tandem duplication (ITD) mice Emily Baileya,b,LiLia, Amy S. Duffieldc, Hayley S. Maa, David L. Husob, and Don Smalla,d,1 Departments of aOncology, cPathology, and dPediatrics, The Johns Hopkins School of Medicine, Baltimore, MD 21231; and bDepartment of Molecular and Comparative Pathobiology, The Johns Hopkins School of Medicine, Baltimore, MD 21205 Edited by Kevin Shannon, University of California, San Francisco, CA, and accepted by the Editorial Board October 23, 2013 (received for review June 24, 2013) FMS-like tyrosine kinase 3 (FLT3) is mutated in approximately one and SH2-containing inositol phosphatase (SHIP), suggesting its third of acute myeloid leukemia cases. The most common FLT3 involvement in the PI3K and mitogen-activated protein kinases mutations in acute myeloid leukemia are internal tandem dupli- (RAS-MAPK) pathway (4–6, 14). Wild-type FLT3 activates STAT5 cation (ITD) mutations in the juxtamembrane domain (23%) at a low level (15). FLT3/ITD mutations activate these same and point mutations in the tyrosine kinase domain (10%). The downstream targets but, in contrast, activate STAT5 at an elevated mutation substituting the aspartic acid at position 838 (equivalent level (16, 17). Evidence from cell lines has shown that FLT3/ITD to the human aspartic acid residue at position 835) with a tyrosine and FLT3/KD mutant signal transduction pathways have some (referred to as FLT3/D835Y hereafter) is the most frequent kinase differences, even though both mutations result in the constitutive domain mutation, converting aspartic acid to tyrosine. Although activation of FLT3 independent of its ligand (3–5, 9, 14, 18). FLT3/ both of these mutations constitutively activate FLT3, patients with KD mutations also induce activation of the RAS, ERK, and AKT an ITD mutation have a significantly poorer prognosis. To eluci- pathways but demonstrate relatively weak STAT5 activity (19). The date the mechanisms behind this prognostic difference, we have differences in signal transduction between FLT3/KD and FLT3/ generated a knock-in mouse model with a D838Y point mutation ITD mutations may help explain the distinctive disease pro- in FLT3 that corresponds to the FLT3/D835Y mutation described in gression and prognosis in leukemias harboring these mutations. humans. Compared with FLT3/ITD knock-in mice, the FLT3/D835Y Cytogenetic, PCR, and sequencing studies show that FLT3 knock-in mice survive significantly longer. The majority of these mutations frequently occur together with mutations/alterations mice develop myeloproliferative neoplasms with a less-aggressive of other genes, including DNA methyltransferase 3a (DNMT3a, phenotype. In addition, FLT3/D835Y mice have distinct hemato- 13.3%), nucleophosmin 1 (NPM1, 6.8%), Wilms tumor 1 (WT1, poietic development patterns. Unlike the tremendous depletion 5%), runt-related transcription factor 1 (RUNX1, 3.5%), mixed- lineage leukemia (MLL, 2.5%), CCAAT/enhancer binding pro- of the hematopoietic stem cell compartment we have observed in α FLT3/ITD mice, FLT3/D835Y mutant mice are not depleted in tein alpha (CEBP , 1.5%) and core-binding factor (CBF, 1.5%) hematopoietic stem cells. Further comparisons of these FLT3/ (20, 21). These studies also show that both the FLT3 mutations (FLT3/ITD or FLT3/KD), as well as the collaborating mutations, D835Y knock-in mice with FLT3/ITD mice should provide an ideal fi platform for dissecting the molecular mechanisms that underlie can have prognostic signi cance. Dissecting the role of each type the prognostic differences between the two different types of of FLT3 mutation in the development of leukemia in the setting FLT3 mutations. of the different cooperating mutations promises to improve our understanding, and thus therapy, of patients with AML. LT3 (FMS-like tyrosine kinase 3, CD135) is a type 3 receptor Significance Ftyrosine kinase that plays important roles in cell survival, proliferation, and differentiation during normal hematopoiesis MEDICAL SCIENCES (1–3). It is one of the most frequently mutated genes in acute FMS-like tyrosine kinase 3 (FLT3) is mutated in approximately myeloid leukemia (AML), with about one-third of AML cases a third of acute myeloid leukemia cases, predominantly in the affected (4–6). Two predominant types of FLT3-activating muta- forms of FLT3/internal tandem duplication mutations in the tions have been described in association with AML. The first juxtamembrane domain or point mutations in the kinase do- main. Although both mutations activate FLT3, they confer involves internal tandem duplication (ITD) mutations mapping to distinctive prognosis. To elucidate the mechanisms behind this the juxtamembrane domain of FLT3, found in about 25% of adult prognostic difference, we have generated a knock-in mouse and 15% of pediatric AML cases (4–9). AML patients with FLT3/ model with a FLT3/D835Y mutation that converts aspartic acid ITD mutations have a poorer prognosis than patients without to tyrosine. Further comparisons of the FLT3/D835Y mice with these mutations. The second type is point mutations, which most the previously generated, otherwise genetically identical FLT3/ frequently occur in the activation loop of the tyrosine kinase do- ∼ – ITD knock-in mice should provide an ideal platform for dis- main (KD). FLT3/KD mutations occur in 8 10% of both adult secting the molecular mechanisms that underlie the prognostic and pediatric AML (10). AML patients who have FLT3/KD differences and for drug screening against these two different mutations have a similar prognosis to AML patients with unmu- types of FLT3 mutations. tated FLT3 (10–13). The most common KD mutation is at codon 835, converting aspartic acid to tyrosine (D835Y). Also seen are Author contributions: E.B., L.L., and D.S. designed research; E.B., L.L., A.S.D., H.S.M., D.L.H., mutations D835V, D835E, and D835H, converting aspartic acid and D.S. performed research; E.B., L.L., A.S.D., H.S.M., D.L.H., and D.S. analyzed data; and to valine, glutamic acid, and histidine at residue 835, respectively, E.B., L.L., and D.S. wrote the paper. mutations converting glycine to glutamic acid at residue 831 The authors declare no conflict of interest. (G831E) and arginine to glutamine at residue 834 (R834Q), as This article is a PNAS Direct Submission. K.S. is a guest editor invited by the Editorial well as the deletion of isoleucine at residue 836 (10–12). Board. On dimerization by FL stimulation, wild-type FLT3 activates See Commentary on page 20860. a series of downstream signaling targets, including the p85 subunit 1To whom correspondence should be addressed. E-mail: [email protected]. of phosphoinositide 3-kinase (PI3K), growth factor receptor-bound This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. protein 2 (GRB2), proto-oncogene tyrosine-protein kinase SRC, 1073/pnas.1310559110/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1310559110 PNAS | December 24, 2013 | vol. 110 | no. 52 | 21113–21118 Downloaded by guest on September 30, 2021 The prevalence and prognostic implications of FLT3 muta- AB tions make them a promising therapeutic target in AML. A number of small-molecule tyrosine kinase inhibitors (TKI) against FLT3 are currently in clinical trials, with varying degrees of clinical responses, but even those patients who respond de- velop resistance to monotherapy (22). One of the mechanisms of acquired resistance to several FLT3 TKIs is the selection for FLT3/KD mutations documented in relapsed patients (23, 24). Further understanding of the mechanisms involved in FLT3 ac- C tivation, signaling, inhibition, and resistance will aid in un- derstanding the complexities of both pediatric and adult AML and help develop more tailored and effective treatments. We have previously generated and characterized a FLT3/ITD knock- Fig. 2. Mice with a FLT3/D835Y mutation develop less aggressive disease in mouse model that consistently develops predominantly compared with FLT3/ITD mutant mice. (A) Kaplan-Meier survival curve of a myeloproliferative neoplastic (MPN) phenotype (25). Here we FLT3/ITD and FLT3/D835Y mice on a C57BL/6 background. P < 0.0001. (B) report on the generation of a FLT3/D835Y knock-in mouse Disease distribution of moribund FLT3/D835Y mice (n = 24). (C) Levels of + + + + model in which an aspartic acid residue was mutated to a tyrosine Mac1 , Mac1 /Gr1 , and Gr1 as a percentage of whole BM in moribund at residue D838Y (corresponding to D835Y in the human gene, FLT3/ITD (n = 20), FLT3/D835Y (n = 21; hemangiosarcoma diagnoses ex- Fig. 1A). In both models, Flt3 is under control of the endogenous cluded), and wild-type (n = 11) controls. Flt3 promoter mimicking physiological expression. By comparing the phenotypic and signaling differences between FLT3/ITD and FLT3/D835Y mice, we hope to continue to explore the distinctive populations or with different cooperating mutations. To de- roles the two mutations play in leukemogenesis and why only the termine whether the prognostic difference reported in humans FLT3/ITD mutation results in poor prognosis. would also be observed in genetically identical mouse models that differ only in the type of FLT3 mutation, we directly com- Results pared FLT3/ITD mice with the newly generated FLT3/D835Y mice. Mice were monitored for survival and killed when mori- Mice with a FLT3/D835Y Mutation Develop MPN That Is Less bund or demonstrating obvious clinical distress. The median Aggressive Than That of FLT3/ITD Mutant Mice. AML patients with survival of the heterozygous FLT3/D835Y mice was 678 d and FLT3/KD mutations develop less-aggressive disease compared ranged from 394 to 826 d. This is prolonged survival compared with those with FLT3/ITD mutations, as evidenced by lower with the heterozygous FLT3/ITD mice that have a median sur- WBC and better prognosis (13). There are a number of potential vival of 430 d (P < 0.0001; Fig.
Load more

Recommended publications
  • Tyrosine Kinase Inhibitors Ameliorate Autoimmune Encephalomyelitis in a Mouse Model of Multiple Sclerosis
    J Clin Immunol DOI 10.1007/s10875-011-9579-6 Tyrosine Kinase Inhibitors Ameliorate Autoimmune Encephalomyelitis in a Mouse Model of Multiple Sclerosis Oliver Crespo & Stacey C. Kang & Richard Daneman & Tamsin M. Lindstrom & Peggy P. Ho & Raymond A. Sobel & Lawrence Steinman & William H. Robinson Received: 23 February 2011 /Accepted: 5 July 2011 # Springer Science+Business Media, LLC 2011 Abstract Multiple sclerosis is an autoimmune disease of development of disease and treat established disease in a the central nervous system characterized by neuroinflam- mouse model of multiple sclerosis. In vitro, imatinib and mation and demyelination. Although considered a T cell- sorafenib inhibited astrocyte proliferation mediated by the mediated disease, multiple sclerosis involves the activation tyrosine kinase platelet-derived growth factor receptor of both adaptive and innate immune cells, as well as (PDGFR), whereas GW2580 and sorafenib inhibited resident cells of the central nervous system, which macrophage tumor necrosis factor (TNF) production medi- synergize in inducing inflammation and thereby demyelin- ated by the tyrosine kinases c-Fms and PDGFR, respec- ation. Differentiation, survival, and inflammatory functions tively. In vivo, amelioration of disease by GW2580 was of innate immune cells and of astrocytes of the central associated with a reduction in the proportion of macro- nervous system are regulated by tyrosine kinases. Here, we phages and T cells in the CNS infiltrate, as well as a show that imatinib, sorafenib, and GW2580—small mole- reduction in the levels of circulating TNF. Our findings cule tyrosine kinase inhibitors—can each prevent the suggest that GW2580 and the FDA-approved drugs imatinib and sorafenib have potential as novel therapeu- : : : tics for the treatment of autoimmune demyelinating O.
    [Show full text]
  • 07052020 MR ASCO20 Curtain Raiser
    Media Release New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment to accelerating progress in cancer care First clinical data from tiragolumab, Roche’s novel anti-TIGIT cancer immunotherapy, in combination with Tecentriq® (atezolizumab) in patients with PD-L1-positive metastatic non- small cell lung cancer (NSCLC) Updated overall survival data for Alecensa® (alectinib), in people living with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC Key highlights to be shared on Roche’s ASCO virtual newsroom, 29 May 2020, 08:00 CEST Basel, 7 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 19 approved and investigational medicines across 21 cancer types, will be presented at the ASCO20 Virtual Scientific Program organised by the American Society of Clinical Oncology (ASCO), which will be held 29-31 May, 2020. A total of 120 abstracts that include a Roche medicine will be presented at this year's meeting. "At ASCO, we will present new data from many investigational and approved medicines across our broad oncology portfolio," said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “These efforts exemplify our long-standing commitment to improving outcomes for people with cancer, even during these unprecedented times. By integrating our medicines and diagnostics together with advanced insights and novel platforms, Roche is uniquely positioned to deliver the healthcare solutions of the future." Together with its partners, Roche is pioneering a comprehensive approach to cancer care, combining new diagnostics and treatments with innovative, integrated data and access solutions for approved medicines that will both personalise and transform the outcomes of people affected by this deadly disease.
    [Show full text]
  • FLT3 Inhibitors in Acute Myeloid Leukemia Mei Wu1, Chuntuan Li2 and Xiongpeng Zhu2*
    Wu et al. Journal of Hematology & Oncology (2018) 11:133 https://doi.org/10.1186/s13045-018-0675-4 REVIEW Open Access FLT3 inhibitors in acute myeloid leukemia Mei Wu1, Chuntuan Li2 and Xiongpeng Zhu2* Abstract FLT3 mutations are one of the most common findings in acute myeloid leukemia (AML). FLT3 inhibitors have been in active clinical development. Midostaurin as the first-in-class FLT3 inhibitor has been approved for treatment of patients with FLT3-mutated AML. In this review, we summarized the preclinical and clinical studies on new FLT3 inhibitors, including sorafenib, lestaurtinib, sunitinib, tandutinib, quizartinib, midostaurin, gilteritinib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG 925, TTT-3002, and FF-10101. New generation FLT3 inhibitors and combination therapies may overcome resistance to first-generation agents. Keywords: FMS-like tyrosine kinase 3 inhibitors, Acute myeloid leukemia, Midostaurin, FLT3 Introduction RAS, MEK, and PI3K/AKT pathways [10], and ultim- Acute myeloid leukemia (AML) remains a highly resist- ately causes suppression of apoptosis and differentiation ant disease to conventional chemotherapy, with a me- of leukemic cells, including dysregulation of leukemic dian survival of only 4 months for relapsed and/or cell proliferation [11]. refractory disease [1]. Molecular profiling by PCR and Multiple FLT3 inhibitors are in clinical trials for treat- next-generation sequencing has revealed a variety of re- ing patients with FLT3/ITD-mutated AML. In this re- current gene mutations [2–4]. New agents are rapidly view, we summarized the preclinical and clinical studies emerging as targeted therapy for high-risk AML [5, 6]. on new FLT3 inhibitors, including sorafenib, lestaurtinib, In 1996, FMS-like tyrosine kinase 3/internal tandem du- sunitinib, tandutinib, quizartinib, midostaurin, gilteriti- plication (FLT3/ITD) was first recognized as a frequently nib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG mutated gene in AML [7].
    [Show full text]
  • The Role of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Sunnie Kim, MD, and Ghassan K
    The Role of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Sunnie Kim, MD, and Ghassan K. Abou-Alfa, MD Dr Kim is a fellow in medical oncology Abstract: Since the approval of the multityrosine kinase inhibitor and hematology at Weill Medical College (TKI) sorafenib (Nexavar, Bayer and Onyx) as the standard of care at Cornell University in New York, New for intermediate to advanced stages of hepatocellular carcinoma York. Dr Abou-Alfa is an associate attend- (HCC), there has been considerable interest in developing more ing at Memorial Sloan-Kettering Cancer Center and an associate professor at Weill potent TKIs to improve morbidity and mortality for patients with Medical College at Cornell University, in HCC. Much of the research on TKIs targets pathways implicated in New York, New York. angiogenesis, given that HCC is a highly vascularized cancer type. It was theorized that the efficacy of sorafenib is primarily attributable Address Correspondence to: to its angiogenesis targets—namely, vascular endothelial growth Ghassan K. Abou-Alfa, MD factor receptors, platelet-derived growth factor receptors, FLT-3, Memorial Sloan-Kettering Cancer Center 300 East 66th St and RAF kinases. Over the past 2 years, several pivotal phase 3 New York, NY 10065 trials of newer TKIs targeting similar pathways have failed to meet E-mail: [email protected] criteria for superiority or noninferiority to sorafenib. Reasons for this may stem from the genetic and biologic heterogeneity of HCC. Genomic studies of tumor samples have shown scarce uniformity in kinase mutations, underscoring the variability that exists in HCC. This beckons the question of whether efforts should shift to other potential targets, either within the realm of TKIs or other targets entirely.
    [Show full text]
  • Sorafenib (Nexavar®) (“Sor AF E Nib”)
    Sorafenib (Nexavar®) (“sor AF e nib”) How the drug is given: by mouth Purpose: stops the growth of cancer cells in kidney cancer, liver cancer, and other cancers How to take the drug by mouth • Take on an empty stomach with a full glass of water. • Take dose at least 1 hour before food or at least 2 hours after food. • Swallow each tablet whole; do not crush or chew them. If you are unable to swallow the tablet, the pharmacist will give you specific instructions. • If you miss a dose, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double dose. • Sorafenib can interfere with many drugs, which may change how this works in your body. Talk with your doctor before starting any new drugs, including over-the-counter drugs, natural products, herbals or vitamins. Storage • Store this medicine at room temperature, away from heat and moisture. Keep this medicine in its original container, out of the reach of children and pets. Things that may occur during treatment 1. You may get a headache. Please talk to your doctor or nurse about what you can take for this. 2. Loose stools or diarrhea may occur within 3 days after the drug is given. You may take loperamide (Imodium A-D®) to help control diarrhea. You may buy this at most drug stores. It is also important to drink more fluids (water, juice, sports drinks). If these do not help, tell your doctor or nurse.
    [Show full text]
  • Sorafenib Inhibits the Imatinib-Resistant KIT Gatekeeper
    Cancer Therapy: Preclinical Sorafenib Inhibits the Imatinib-Resistant KIT T670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor Tianhua Guo,1Narasimhan P. Agaram,1Grace C. Wong,1Glory Hom,1David D’Adamo,2 Robert G. Maki,2 Gary K. Schwartz,2 Darren Veach,5 Bayard D. Clarkson,5 Samuel Singer,3 Ronald P. DeMatteo,3 Peter Besmer,4 and Cristina R. Antonescu1,4 Abstract Purpose: Resistance is commonly acquired in patients with metastatic gastrointestinal stromal tumor who are treated with imatinibmesylate, often due to the development of secondary muta- tions in the KIT kinase domain. We sought to investigate the efficacy of second-line tyrosine kinase inhibitors, such as sorafenib, dasatinib, and nilotinib, against the commonly observed imatinib-resistant KIT mutations (KIT V654A,KITT670I,KITD820Y,andKIT N822K) expressed in the Ba/F3 cellular system. Experimental Design: In vitro drug screening of stable Ba/F3 KIT mutants recapitulating the genotype of imatinib-resistant patients harboring primary and secondary KIT mutations was investigated. Comparison was made to imatinib-sensitive Ba/F3 KIT mutant cells as well as Ba/F3 cells expressing only secondary KIT mutations.The efficacy of drug treatment was evalu- ated by proliferation and apoptosis assays, in addition to biochemical inhibition of KITactivation. Results: Sorafenibwas potent against all imatinib-resistant Ba/F3 KIT double mutants tested, including the gatekeeper secondary mutation KITWK557-8del/T670I, which was resistant to other kinase inhibitors. Although all three drugs tested decreased cell proliferation and inhibited KIT activation against exon 13 (KITV560del/V654A) and exon 17 (KITV559D/D820Y) double mutants, nilotinibdid so at lower concentrations. Conclusions: Our results emphasize the need for tailored salvage therapy in imatinib-refractory gastrointestinal stromal tumors according to individual molecular mechanisms of resistance.
    [Show full text]
  • Sorafenib Efficacy in Thymic Carcinomas Seems Not to Require C-KIT Or PDGFR-Alpha Mutations
    ANTICANCER RESEARCH 34: 5105-5110 (2014) Sorafenib Efficacy in Thymic Carcinomas Seems Not to Require c-KIT or PDGFR-alpha Mutations MARIA PAGANO1, NURIA MARIA ASENSIO SIERRA1, MICHELE PANEBIANCO1, GIULIO ROSSI2, ROBERTA GNONI1, GIANCARLO BISAGNI1 and CORRADO BONI1 Department of Oncology and Advanced Technologies, 1Oncology Unit and 2Operative Unit of Pathology, Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy Abstract. Purpose: To retrospectively evaluate sorafenib in the United States) (1), they are among the most common activity and safety in patients with metastatic thymic mediastinal primary tumours with up to 50% of anterior carcinoma (TC) and to correlate outcome with c-KIT and mediastinal masses proving to be of thymic origin. Males PDGFR-alpha mutational status. Patients and Methods: have a slightly higher risk of developing thymic carcinomas Patients with metastatic thymic carcinoma treated with than females and this risk rises with age, reaching a peak in sorafenib after at least one prior line of chemotherapy were the seventh decade of life. included. Objective response rate (ORR) and toxicity were Thymic carcinomas (TC) are aggressive neoplasms with evaluated. Analysis of c-KIT and PDGFR-alpha mutational poor prognosis and limited effective therapeutic options status was performed retrospectively. Results: From (2-5). October 2007 to August 2011, 5 patients with metastatic In early stages, surgery is the standard treatment, while thymic carcinoma were evaluated. A median of 8 cycles of systemic chemotherapy is mainly reserved for patients with sorafenib (range=3–29) were administered. Two patients an unresectable or recurrent disease (1, 2). (40%) displayed a partial response (PR), two patients Current regimens consist of a combination of drugs almost presented stable disease (SD), while one patient had always including a platinum compound; other effective drugs progression.
    [Show full text]
  • The Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma: Theoretical Basis and Therapeutic Aspects
    Signal Transduction and Targeted Therapy www.nature.com/sigtrans REVIEW ARTICLE OPEN The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects Weiwei Tang1, Ziyi Chen2, Wenling Zhang3, Ye Cheng1, Betty Zhang4, Fan Wu1, Qian Wang 1, Shouju Wang5, Dawei Rong2, F. P. Reiter6,7, E. N. De Toni6,7 and Xuehao Wang2 Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC), sorafenib is currently an effective first-line therapy. Unfortunately, the development of drug resistance to sorafenib is becoming increasingly common. This study aims to identify factors contributing to resistance and ways to mitigate resistance. Recent studies have shown that epigenetics, transport processes, regulated cell death, and the tumor microenvironment are involved in the development of sorafenib resistance in HCC and subsequent HCC progression. This study summarizes discoveries achieved recently in terms of the principles of sorafenib resistance and outlines approaches suitable for improving therapeutic outcomes for HCC patients. Signal Transduction and Targeted Therapy (2020) ;5:87 https://doi.org/10.1038/s41392-020-0187-x 1234567890();,: INTRODUCTION received approval as second-line treatments after sorafenib.9–12 Hepatocellular carcinoma (HCC) is the second leading cause of Checkpoint inhibitors have also opened new strategies for the cancer-related mortality globally and usually presents in patients treatment of HCC.13,14 Recently reported results from the with chronic liver inflammation associated with viral infection, IMbrave150 study (NCT03434379) show potential for the combi- alcohol overuse, or metabolic syndrome.1,2 Significant progress nation of atezolizumab with bevacizumab to expand the has been made in HCC prevention, diagnosis and treatment in the treatment options in first-line therapy for HCC.15 However, past.
    [Show full text]
  • Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
    cancers Review Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Sara M. Atwa 1,2, Margarete Odenthal 3 and Hend M. El Tayebi 2,* 1 Pharmaceutical Biology Department, German University in Cairo, Cairo 11865, Egypt; [email protected] 2 Molecular Pharmacology Research Group, Department of Pharmacology and Toxicology, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt 3 Institute for Pathology, University Hospital Cologne, 50924 Cologne, Germany; [email protected] * Correspondence: [email protected] Simple Summary: Hepatocellular carcinoma (HCC) represents a worldwide health challenge, rank- ing globally as the third most common cause of cancer-related mortality. Current advancements in the HCC therapeutic armamentarium succeeded in challenging HCC conventional therapy. Systemic therapies including tyrosine kinase inhibitors and immune checkpoint inhibitors (ICIs) come at the forefront of novel HCC therapeutic modalities. However, emerging drug resistance remains an obstacle during HCC therapy. According to the ongoing genomic analysis of HCC, a complex mutational landscape lies behind HCC pathogenesis and hence, affects the response of the tumor to the applied therapy. This review aims at categorizing and summarizing the different resistance Citation: Atwa, S.M.; Odenthal, M.; mechanisms confronting tyrosine kinase inhibitors, represented by sorafenib, as well as ICIs, during M. El Tayebi, H. Genetic HCC therapy. In addition, giving an insight into how genomic heterogeneity can influence the Heterogeneity, Therapeutic Hurdle response of HCC to the aforementioned therapies. Confronting Sorafenib and Immune Checkpoint Inhibitors in Abstract: Despite the latest advances in hepatocellular carcinoma (HCC) screening and treatment Hepatocellular Carcinoma.
    [Show full text]
  • Clinical Benefits and Safety of FMS-Like Tyrosine Kinase 3
    SYSTEMATIC REVIEW published: 03 June 2021 doi: 10.3389/fonc.2021.686013 Clinical Benefits and Safety of FMS-Like Tyrosine Kinase 3 Inhibitors in Various Treatment Stages of Acute Myeloid Leukemia: A Systematic Review, Meta-Analysis, and Network Meta-Analysis Edited by: Qingyu Xu 1,2, Shujiao He 1 and Li Yu 1* Adria´ n Mosquera Orgueira, University Hospital of Santiago 1 Department of Hematology and Oncology, International Cancer Center, Shenzhen Key Laboratory, Shenzhen University de Compostela, Spain General Hospital, Shenzhen University Clinical Medical Academy, Shenzhen University Health Science Center, 2 Reviewed by: Shenzhen, China, Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany Claudio Cerchione, Istituto Scientifico Romagnolo per lo Studio e il Trattamento dei Tumori Background: Given the controversial roles of FMS-like tyrosine kinase 3 inhibitors (FLT3i) (IRCCS), Italy Manuela Piazzi, in various treatment stages of acute myeloid leukemia (AML), this study was designed to National Research Council (CNR), assess this problem and further explored which FLT3i worked more effectively. Italy Bruno Quesnel, Methods: A systematic review, meta-analysis and network meta-analysis (NMA) were Centre Hospitalier Regional et conducted by filtering PubMed, Embase, Cochrane library, and Chinese databases. We Universitaire de Lille, France included studies comparing therapeutic effects between FLT3i and non-FLT3i group in *Correspondence: fi Li Yu AML, particularly FLT3(+) patients, or demonstrating the ef ciency of allogeneic [email protected] hematopoietic stem cell transplantation (allo-HSCT) in FLT3(+) AML. Relative risk (RR) with 95% confidence intervals (CI) was used for estimating complete remission (CR), early Specialty section: This article was submitted to death and toxicity.
    [Show full text]
  • For Health Professionals Who Care for Cancer Patients
    May 2014 Volume 17, Number 5 For Health Professionals Who Care For Cancer Patients Inside This Issue: . Editor’s Choice – New Programs: Breast – Trastuzumab Patient Handouts (Chinese, Punjabi): Emtansine for Metastatic Breast Cancer (UBRAVKAD); Cyclophosphamide IV , Etoposide IV, Hydroxyurea Leukemia/BMT – Arsenic Trioxide for Untreated . Benefit Drug List – New: UBRAVKAD, HLHETCSPA, (ULKATOATRA, ULKATOP) and Relapsed (ULKATOR) Acute ULKATOATRA, ULKTOP, ULKTOR, SAAVTC; Revised: Promyelocytic Leukemia; Lymphoma – Etoposide, LYALEM Dexamethasone and Cyclosporine for Hemophagocytic . Systemic Therapy Update – Editorial Board Lymphohistiocytosis (HLHETCSPA); Sarcoma – Topotecan Membership and Cyclophosphamide for Relapsed Neuroblastoma, Ewing’s Sarcoma, Osteogenic Sarcoma or . List of New and Revised Protocols, Provincial Pre‐ Rhabdomyosarcoma (SAAVTC); Highlights of Changes in Printed Orders and Patient Handouts – New: Protocols, PPPOs, and Patient Handouts: Lung – Expanding UBRAVKAD, HLHETCSPA, HNAVP, HNNAVP, Eligibility Criteria of Maintenance Pemetrexed in Advanced UHNNAVPC, ULKATOATRA, ULKTOP, ULKTOR, Non‐Small Cell Lung Cancer (ULUAVPMTN) ULUAVCRIZ, SAAVTC, SCDMAB; Revised: UBRAVERIB, BRAVEXE, BRAVT7, UBRAVLCAP, UBRAVTCAP, . Provincial Systemic Therapy Program – Updates to BCCA CNAJTZRT, CNOCTLAR, GIEFUPRT, GIPAJGEM, GIRCRT, Policy on Physician Coverage for Medical Emergencies GOOVDDCAT, UGUAXIT, UGUPENZ, UGUSORAF, During Delivery of Selective Chemotherapy Drugs HNAVP, UHNLADCF, HNNAVPE, UHNLACETRT, . Communities Oncology Network –
    [Show full text]
  • Second-Line Treatment for Renal Cell Cancer
    British Journal of Cancer (2012) 106, 617 – 618 & 2012 Cancer Research UK All rights reserved 0007 – 0920/12 www.bjcancer.com Editorial Second-line treatment for renal cell cancer ,1 1 1 G Di Lorenzo* , S De Placido and C Buonerba 1Dipartimento di Endocrinologia ed Oncologia Clinica e Molecolare, Universita` Federico II, Napoli, Italy British Journal of Cancer (2012) 106, 617 – 618. doi:10.1038/bjc.2011.611 www.bjcancer.com & 2012 Cancer Research UK In metastatic renal cell carcinoma (mRCC), the transition to the numerically superior to that obtained with second-line sorafenib in targeted therapy era has made available a variety of effective new 52 patients with sunitinib-refractory mRCC by Di Lorenzo et al agents, including vascular endothelial growth factor tyrosine (2009). Importantly, although all of the patients enrolled in the kinase receptor (VEGF-TKR) inhibitors, such as sunitinib, Di Lorenzo trial had received a single agent for metastatic disease, pazopanib, sorafenib; anti-VEGF monoclonal antibody bevacizu- 79% of patients in the RECORD-1 trial had received more than one mab; and mTOR (mammalian target of rapamycin) inhibitors, medication for systemic disease at enrollement, including suniti- everolimus and temsirolimus. A statistically significant improve- nib, sorafenib or interferon. An indirect comparison analysis was ment in progression-free survival (PFS) was obtained with each of performed by matching patients enrolled in these two trials for these six biological drugs in well-conducted phase III trials, in histology, prior treatment, and MSKCC risk score showed that comparison with either interferon alone (in the first-line setting) everolimus was associated with a statistically significant improved or placebo (in the second-line setting).
    [Show full text]